These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

978 related articles for article (PubMed ID: 29307283)

  • 1. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Ludwig MD; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Featured Article: Serum [Met
    Ludwig MD; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2017 Sep; 242(15):1524-1533. PubMed ID: 28766982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
    Hammer LA; Waldner H; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2016 Jan; 241(1):71-8. PubMed ID: 26202376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis.
    McLaughlin PJ; McHugh DP; Magister MJ; Zagon IS
    BMC Immunol; 2015 Apr; 16():24. PubMed ID: 25906771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum [Met
    Ludwig MD; Zagon IS; McLaughlin PJ
    Brain Res Bull; 2017 Sep; 134():1-9. PubMed ID: 28647454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis.
    Campbell AM; Zagon IS; McLaughlin PJ
    Brain Res Bull; 2013 Jan; 90():43-51. PubMed ID: 22985690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent blockade of OGFr and treatment of autoimmune disorders.
    Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2018 Dec; 243(17-18):1323-1330. PubMed ID: 30541348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
    Rahn KA; McLaughlin PJ; Zagon IS
    Brain Res; 2011 Mar; 1381():243-53. PubMed ID: 21256121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Met
    Patel C; Meadowcroft MD; Zagon IS; McLaughlin PJ
    Brain Res Bull; 2020 Dec; 165():246-252. PubMed ID: 33141073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of treatment with an endogenous opioid alters immune response and spinal cord pathology in female mice with experimental autoimmune encephalomyelitis.
    Patel C; Zagon IS; Pearce-Clawson M; McLaughlin PJ
    J Neurosci Res; 2022 Feb; 100(2):551-563. PubMed ID: 34821408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis.
    Campbell AM; Zagon IS; McLaughlin PJ
    Brain Res; 2012 Sep; 1472():138-48. PubMed ID: 22820301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis.
    Zagon IS; Rahn KA; Bonneau RH; Turel AP; McLaughlin PJ
    Brain Res; 2010 Jan; 1310():154-61. PubMed ID: 19931226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications.
    Zagon IS; Sassani JW; Purushothaman I; McLaughlin PJ
    Exp Biol Med (Maywood); 2021 Mar; 246(5):629-636. PubMed ID: 33203224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
    McLaughlin PJ; Zagon IS
    Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor.
    Hammer LA; Zagon IS; McLaughlin PJ
    Brain Res Bull; 2013 Sep; 98():122-31. PubMed ID: 23973432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
    Donahue RN; McLaughlin PJ; Zagon IS
    Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
    Zagon IS; Donahue R; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium.
    Zagon IS; Ruth TB; McLaughlin PJ
    Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan; 282(1):24-37. PubMed ID: 15584033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.